How Much Growth Is Left in OTC?
Mature OTC markets are still growing on paper, but a widening gap between price and real demand raises questions about how much growth is actually left.
HBW Insight - March 25, 2026

Spring In The Step Is Back For Neuroscience Biotechs
Panellists at BIO-Europe Spring in Lisbon have welcomed the resurgence of interest in brain-related disorders
Scrip - March 25, 2026

Daiichi Sankyo Looks To Deploy ‘Smarter’ R&D Approach To ADCs
As a pioneer in antibody-drug conjugates, Daiichi Sankyo has seen both breakthroughs and setbacks in advancing the modality. CEO Ken Keller told In Vivo the company had turned to next generation biomarker technologies to navigate these challenges and sharpen its R&D strategy.
In Vivo - March 25, 2026

Novo And United’s Triple-G Agonist Scores In Diabetes Study
Phase II results follow close behind corresponding study in obesity, but show less to scare Novo Nordisk’s big rivals Lilly.
Scrip - March 25, 2026

GE HealthCare’s Photonova Spectra FDA Clearance Heats Up PCCT Race With Siemens
GE HealthCare has spent $5.1bn and decades developing its answer to Siemens Healthineers' photon-counting CT dominance. The FDA just cleared it. Now the harder question – whether the Photonova Spectra's Deep Silicon technology can convert claims into market share – begins.
Medtech Insight - March 25, 2026

Medtronic Expands OmniaSecure Approval to Left Bundle Branch Pacing, Raising Competitive Stakes
A new FDA indication for Medtronic’s OmniaSecure defibrillation lead marks a step forward for conduction-system pacing, enabling defibrillator-equipped systems to target a portion of the heart known as the left bundle branch area.
Medtech Insight - March 25, 2026

Boehringer Issues Warning To Innovation-Unfriendly Europe
The Germany-based family-owned company, which has posted a decent set of financials for 2025 driven by Jardiance and Ofev, is particularly concerned about the red tape involved in getting clinical trials off the ground.
Scrip - March 25, 2026

Ocugen Lines Up Phase III Macular Degeneration Study For Gene Therapy OCU410
The planned Phase III trial will be key to validating OCU410’s efficacy and safety in a broader patient population.
Scrip - March 25, 2026

IGBA Picks Gaunt As New Secretary General
The IGBA has named former Medicines for Europe, Novartis and Sandoz executive Ana Gaunt as the new secretary general of the global generics and biosimilars industry association.
Generics Bulletin - March 25, 2026

Merck To Buy Terns For $6.7bn, Boosting Blood Cancer Portfolio Further
Its latest acquisition adds to Merck’s arsenal of hemato-oncology candidates, with TERN-701 aiming to challenge Novartis's Scemblix.
Scrip - March 25, 2026

‘More Can Be Done’ – AAM’s Keeton On Reshaping The US Biosimilars Market
Despite recent wins on streamlining and interchangeability, the US biosimilars industry continues to face challenges such as IRA price negotiation, dysfunctional pricing dynamics and PBM distortions, says AAM Biosimilars Council chief Alex Keeton.
Generics Bulletin - March 25, 2026

Celltrion Ramps Capacity To Power Global Biosimilars Expansion
Celltrion will invest KRW1.23trn in two new Songdo plants, adding 180,000L of capacity as part of a broader Korea-US expansion that will lift global drug-substance capacity to 571,000L and support pipeline growth and CMO ambitions.
Generics Bulletin - March 25, 2026

Lupin CEO And MD On Best-In-Class Innovation, Top Spot Ambition And Father’s Legacy
Lupin’s CEO Vinita Gupta and MD Nilesh Gupta outline the company’s innovation agenda, strategy on GLP-1 drugs including fortnightly candidate bofanglutide, plans to get to number one in the domestic market and the legacy of their father in this podcast interview.
Scrip - March 25, 2026

Could CAR-T Cells Cure Some Autoimmune Diseases?
Clinical evidence points to immune system ‘reset’ and durable remission. Investors have taken note and the deals have followed.
In Vivo - March 25, 2026

The Commercial Test: Psychedelics Move From Fringe Science To Doctor’s Office
Compass Pathways, now leading the race toward regulatory approval for a classic psychedelic, mapped out its strategy behind what could become one of the industry’s more unconventional drug launches.
In Vivo - March 25, 2026

From Super Bowl to CGT Nerve Centre And Trial Timelines: How Big Pharma’s India GCCs Add Value
Leaders from Novartis, AstraZeneca, Eli Lilly and Novo Nordisk outlined how global capability centers in India are delivering tangible benefits across the value chain, from playing a key role at an awareness campaign during the US Super Bowl LX to sharply compressing study go-live timelines.
Scrip - March 25, 2026

Multiple Chinese HER2 ADCs Close In On Enhertu In Breast Cancer
Clinical and regulatory developments in breast cancer for multiple HER-2-targeting antibody-drug conjugates from Chinese firms look set to up the competition for Enhertu.
Scrip - March 25, 2026

China Companies’ Out-Licensing Deals ‘Rational’ But Partly Policy-Driven
The acceleration of commercial health insurance was included in national development plans for 2026 released by the Chinese government in the recent “Two Sessions” policy meetings, and appears key for the next generation of innovative drugs to achieve domestic success.
Scrip - March 25, 2026